Shenzhen Salubris Pharmaceuticals Co Ltd (002294) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shenzhen Salubris Pharmaceuticals Co Ltd (002294) has a cash flow conversion efficiency ratio of 0.045x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥400.70 Million ≈ $58.63 Million USD) by net assets (CN¥8.93 Billion ≈ $1.31 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 002294 equity financing ratio to measure how much of total assets are equity-financed.
Shenzhen Salubris Pharmaceuticals Co Ltd - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Shenzhen Salubris Pharmaceuticals Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Shenzhen Salubris Pharmaceuticals Co Ltd to evaluate the quality of earnings relative to operating cash generation.
Shenzhen Salubris Pharmaceuticals Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shenzhen Salubris Pharmaceuticals Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bachem Holding AG
SW:BANB
|
0.127x |
|
Gerdau SA ADR
NYSE:GGB
|
0.028x |
|
YANGTZE OPT.FIB.AND CAB.H
F:1YO
|
N/A |
|
Black Hills Corporation
NYSE:BKH
|
0.044x |
|
3SBio Inc
F:83B
|
0.019x |
|
GREEK O.FOOTB. ADR 1/2
F:GF8A
|
0.457x |
|
Shenghe Resources Holding Co Ltd
SHG:600392
|
0.024x |
|
ICL Israel Chemicals Ltd
TA:ICL
|
0.048x |
Annual Cash Flow Conversion Efficiency for Shenzhen Salubris Pharmaceuticals Co Ltd (2006–2024)
The table below shows the annual cash flow conversion efficiency of Shenzhen Salubris Pharmaceuticals Co Ltd from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see Shenzhen Salubris Pharmaceuticals Co Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥8.75 Billion ≈ $1.28 Billion |
CN¥1.19 Billion ≈ $173.59 Million |
0.136x | +25.52% |
| 2023-12-31 | CN¥8.06 Billion ≈ $1.18 Billion |
CN¥869.79 Million ≈ $127.28 Million |
0.108x | -11.28% |
| 2022-12-31 | CN¥7.98 Billion ≈ $1.17 Billion |
CN¥970.80 Million ≈ $142.06 Million |
0.122x | -17.36% |
| 2021-12-31 | CN¥8.05 Billion ≈ $1.18 Billion |
CN¥1.18 Billion ≈ $173.40 Million |
0.147x | -40.08% |
| 2020-12-31 | CN¥5.59 Billion ≈ $818.24 Million |
CN¥1.37 Billion ≈ $201.11 Million |
0.246x | +8.75% |
| 2019-12-31 | CN¥6.67 Billion ≈ $975.50 Million |
CN¥1.51 Billion ≈ $220.47 Million |
0.226x | +15.83% |
| 2018-12-31 | CN¥6.87 Billion ≈ $1.01 Billion |
CN¥1.34 Billion ≈ $196.18 Million |
0.195x | -17.57% |
| 2017-12-31 | CN¥6.16 Billion ≈ $901.18 Million |
CN¥1.46 Billion ≈ $213.31 Million |
0.237x | -9.93% |
| 2016-12-31 | CN¥5.46 Billion ≈ $798.98 Million |
CN¥1.43 Billion ≈ $209.96 Million |
0.263x | +16.85% |
| 2015-12-31 | CN¥4.70 Billion ≈ $687.12 Million |
CN¥1.06 Billion ≈ $154.53 Million |
0.225x | -13.27% |
| 2014-12-31 | CN¥3.79 Billion ≈ $554.32 Million |
CN¥982.25 Million ≈ $143.73 Million |
0.259x | +21.59% |
| 2013-12-31 | CN¥3.13 Billion ≈ $458.73 Million |
CN¥668.52 Million ≈ $97.83 Million |
0.213x | +6.65% |
| 2012-12-31 | CN¥2.61 Billion ≈ $381.44 Million |
CN¥521.21 Million ≈ $76.27 Million |
0.200x | +56.74% |
| 2011-12-31 | CN¥2.13 Billion ≈ $312.36 Million |
CN¥272.32 Million ≈ $39.85 Million |
0.128x | +27.50% |
| 2010-12-31 | CN¥1.87 Billion ≈ $272.96 Million |
CN¥186.65 Million ≈ $27.31 Million |
0.100x | +20.96% |
| 2009-12-31 | CN¥1.62 Billion ≈ $237.55 Million |
CN¥134.28 Million ≈ $19.65 Million |
0.083x | -72.08% |
| 2008-12-31 | CN¥262.90 Million ≈ $38.47 Million |
CN¥77.89 Million ≈ $11.40 Million |
0.296x | -18.02% |
| 2007-12-31 | CN¥145.96 Million ≈ $21.36 Million |
CN¥52.75 Million ≈ $7.72 Million |
0.361x | +220.57% |
| 2006-12-31 | CN¥106.48 Million ≈ $15.58 Million |
CN¥12.00 Million ≈ $1.76 Million |
0.113x | -- |
About Shenzhen Salubris Pharmaceuticals Co Ltd
Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines and medical devices in China. The company offers drugs for various therapeutic fields, such as thrombosis, hypertension and related diseases, osteoporosis, and infections, as well as anti-osteolysis, antiallergic, antiepileptic, and antidepressant medicines. It also develops Sacubit… Read more